drugset
drugset / Trial / NCT01611428

Absolute Bioavailability Study With Ipragliflozin

NCT01611428 ↗

Phase 1 Completed 14 enrolled Astellas Pharma Europe B.V.
RandomizedCrossoverOpen-labelBasic science

Summary

A study to assess the absolute bioavailability of ipragliflozin in healthy subjects.

Timeline

Start
2011-06
Primary completion
2011-07
Completion
2011-07

Drugs

EvaluationDrugModalityDoseRoute
Subject ipragliflozin Small molecule — Oral

Indications

No indication recorded.